Latest news with #SamuelChen
Yahoo
3 days ago
- Business
- Yahoo
Regencell's 82,000% Surge: The $33 Billion Stock Rally That Nobody Can Explain
When Regencell Bioscience (NASDAQ:RGC) surged 82,000%, it wasn't on the back of a blockbuster drug or FDA approval. It was something far stranger. A small, loss-making traditional Chinese medicine firm with a vacant chief medical officer post and no revenue catalyst suddenly became a $33 billion paper giantat least for a few days. At the peak, founder and CEO Yat-Gai Au's stake eclipsed the wealth of Hong Kong's richest tycoons. He wasn't at the office. No press conference. No update. Then came the crash. As of June 26, the stock has fallen 74%, dragging Au's fortune down to $8.6 billion. Warning! GuruFocus has detected 2 Warning Signs with RGC. The company's fundamentals don't justify its viral rise. Regencell markets herbal formulas for ADHD and autism, developed by Au's father, under the trademark Brain Theory. It posted net losses of $4.4 million in fiscal 2024 and $6.1 million in 2023. Yet it managed to outshine every major healthcare brand on Instagramthanks in part to Taylor Swift ticket giveaways. Its second-largest shareholder? A firm tied to Zoom early investor Samuel Chen. Chen, along with his family, also controls Taiwan's Polaris Group and holds a major stake in IC firm Sonix Technology. None of them are talking. And neither is Regencell. Now regulators might start asking the questions retail investors already are. With no news, no insider filings, and no scientific breakthroughs, the stock's behavior has triggered interest from market observers. Both the SEC and Finra have automated tools for flagging anomalies like this, and experts say it's exactly the kind of movement that draws scrutiny. On June 4, the SEC even floated a proposal to tighten rules on foreign private issuerscompanies like Regencell that operate overseas but trade in the U.S. Whether the rally was driven by low float dynamics, social media virality, or something more problematic remains to be seen. But one thing's certain: for investors, this was a $33 billion lesson in how fast the music can stop. This article first appeared on GuruFocus.
Yahoo
30-05-2025
- Health
- Yahoo
AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics. SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus have entered a Memorandum of Understanding to evaluate a Quality Control workflow solution for urine cytology. The partnership aims to demonstrate the integration of artificial intelligence into the urine cytology workflow, enhancing diagnostic consistency, efficiency, and scalability. AIxMed's experience in AI-based cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come together to provide an end-to-end solution for research-use only cytology analysis. "We are thrilled to collaborate with CorePlus in demonstrating how AIxURO can seamlessly integrate into their digital pathology workflow. This effort builds on the success of our previous studies and marks an important milestone toward modernizing cytology quality control (QC) through digital and AI tools," said Samuel Chen, CEO of AIxMed. "AIxURO offers significant time savings with consistent results. Integrating our scanner with real-time AI-based QC checks significantly improves efficiency and diagnostic accuracy. Precision cytology is no longer a vision—it's reality," said Mariano de Socarraz, Founder, and CEO of CorePlus. The scarcity of cytologists and the manual process involved in cell characterization necessitate the development of advanced tools to enhance workflow and offer both quantitative and qualitative insights. AI-driven computational tools have the potential to provide these valuable insights and enable the processing of a greater number of slides with the existing workforce. To learn more about these solutions or to request a demonstration, please visit About AIxMedFounded in 2018, AIxMed is creating a roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform. This solution simplifies clinical workflows and richly strengthens the quality of healthcare by aiding critical decision support during clinical diagnosis and monitoring. To learn more visit About CorePlusCorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. To learn more visit View original content to download multimedia: SOURCE AIxMed, Inc.
